1,442 Shares in argenex SE $ARGX Acquired by Shepherd Street Advisors LLC

Shepherd Street Advisors LLC bought a new position in argenex SE (NASDAQ:ARGX) in the fourth quarter, according to its most recent filing with the SEC. The firm bought 1,442 shares of the company’s stock, valued at approximately $1,213,000. argenex makes up 1.2% of Shepherd Street Advisors LLC’s investment portfolio, making the stock its 28th largest position.

Other institutional investors also recently bought and sold shares of the company. American Century Companies Inc. boosted its stake in argenex by 11.6% in the 3rd quarter. American Century Companies Inc. now owns 229,770 shares of the company’s stock worth $169,474,000 after purchasing an additional 23,864 shares in the last quarter. Allianz Asset Management GmbH boosted its stake in argenex by 21.3% in the 3rd quarter. Allianz Asset Management GmbH now owns 3,671 shares of the company’s stock worth $2,708,000 after purchasing an additional 645 shares in the last quarter. US Bancorp DE raised its position in argenex by 37.2% during the 3rd quarter. US Bancorp DE now owns 7,073 shares of the company’s stock worth $5,217,000 after buying an additional 1,919 shares during the last quarter. Sands Capital Management LLC purchased a new position in argenex during the 3rd quarter worth approximately $12,262,000. Finally, Fiera Capital Corp raised its position in argenex by 12.1% during the 3rd quarter. Fiera Capital Corp now owns 177,654 shares of the company’s stock worth $131,030,000 after buying an additional 19,180 shares during the last quarter. 60.32% of the stock is currently owned by institutional investors and hedge funds.

argenex Price Performance

NASDAQ:ARGX opened at $802.17 on Wednesday. The firm has a market cap of $49.89 billion, a price-to-earnings ratio of 35.72, a price-to-earnings-growth ratio of 1.32 and a beta of 0.47. The company has a 50 day moving average price of $782.33 and a 200-day moving average price of $814.51. argenex SE has a 1-year low of $510.05 and a 1-year high of $934.62.

argenex (NASDAQ:ARGX) last posted its earnings results on Tuesday, March 31st. The company reported $5.52 earnings per share for the quarter. The firm had revenue of $1.31 billion during the quarter. argenex had a net margin of 31.31% and a return on equity of 33.28%. On average, sell-side analysts anticipate that argenex SE will post 25.34 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. Deutsche Bank Aktiengesellschaft raised shares of argenex from a “hold” rating to a “buy” rating in a research report on Tuesday, March 10th. Citizens Jmp raised their price target on shares of argenex from $925.00 to $944.00 and gave the stock a “market outperform” rating in a research report on Friday, February 27th. Glj Research raised shares of argenex to a “strong-buy” rating in a research report on Friday, April 3rd. Oppenheimer reduced their price target on shares of argenex from $1,060.00 to $1,014.00 and set an “outperform” rating for the company in a research report on Thursday, April 2nd. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of argenex in a research report on Monday, April 20th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, argenex has a consensus rating of “Moderate Buy” and a consensus price target of $1,019.50.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.